Versant Spin-Off Delivers 5% FCF Yield, 40% Below Peers
Versant’s May 2026 spin-off of its drug development unit delivered a standalone free cash flow yield of 5%, compared with the 8% peer average. This 40% valuation gap suggests a potential 25% upside if cash flow multiples re-rate over the next year.
1. Spin-Off Execution
In May 2026, Versant completed the spin-off of its drug development unit, distributing standalone shares to existing investors and establishing independent financial reporting.
2. Valuation Implications
The newly independent entity posted a 5% free cash flow yield on an annualized basis, 40% below the 8% average among comparable peers, suggesting potential undervaluation and rerating catalysts.
Related News
VBCJ
Vanguard BondBuilder Corporate ETFs amass $242M, boosting segment to $70B
VBCJ•
EXOD
Exodus Movement April XO Swap Volume Up 44% to $98M, Global Pay Launch
EXOD•
KDP
Keurig Dr Pepper Sets $0.23 Dividend, CEO to Present at June 3 Conference
KDP•
T
AT&T Commits $19 B to California Fiber and 1,200 New Cell Sites by 2030
T•
ATOS
Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication
ATOS•
Sources
F